High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab
Purpose We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy. Methods In this retrospective study, the pretreatment serum IL-6 and...
Gespeichert in:
| Veröffentlicht in: | Surgery today (Tokyo, Japan) Japan), 2017-04, Vol.47 (4), p.483-489 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 4 |
| container_start_page | 483 |
| container_title | Surgery today (Tokyo, Japan) |
| container_volume | 47 |
| creator | Hara, Masayasu Nagasaki, Takaya Shiga, Kazuyoshi Takahashi, Hiroki Takeyama, Hiromitsu |
| description | Purpose
We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy.
Methods
In this retrospective study, the pretreatment serum IL-6 and plasma vascular endothelial growth factor (VEGF) levels were measured in 113 patients with metastatic CRC. The cut-off values for these measurements, as determined by a receiver operating characteristic curve analysis, were 4.3 and 66 pg/mL, respectively. The median follow-up period was 19 months (range 1–40 months). Sixty-three patients had primary cancer, and 38 had a metachronous recurrence. Thirty patients underwent curative resection, and 71 underwent chemotherapy, 53 of whom received bevacizumab-containing chemotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier and multivariate Cox proportional hazards regression analyses.
Results
The plasma VEGF levels and positive
KRAS
mutation status were not associated with the outcomes. However, high serum IL-6 levels were significantly associated with poorer OS and PFS in comparison to low serum IL-6 levels. A Cox proportional hazards regression analysis showed that high serum IL-6 levels were an independent risk factor for a poor outcome.
Conclusion
In patients with metastatic CRC, high pretreatment serum IL-6 levels were associated with a poor outcome and bevacizumab resistance. |
| doi_str_mv | 10.1007/s00595-016-1404-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859730416</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859730416</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-c25ff165920d0fb950dea5e8d25ac942d1d67b9364d4146476f0f7d3d20af8b33</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCD-CC5sglYDuOnXBDFdBKlbjA2XLscTclsYPtLCr_iH-Jt1s4chq9eW-eNPoIecXoW0apepcp7YauoUw2TFDRqCdkx0QrG96z9inZ0UGwhvGBnZHznO8o5aKn9Dk546oTg1JqR35fTbd7yJi2BWY84JwhephCwTTj9n0KjawKVlMmDCXDz6nswbiDCRYdxAQLFpNLtS3YOMeEtpgZ7NFP76HsEdD7uoQYHlTcio0LggnuQSfMawwZoUSwe1xiXSaz3sM6bxlGPBg7_doWM74gz7yZM758nBfk26ePXy-vmpsvn68vP9w0tpV9aSzvvGeyGzh11I9DRx2aDnvHO2MHwR1zUo1DK4UTTEihpKdeudZxanw_tu0FeXPqXVP8sWEuepmyxXk2AeOWNeu7QbVUMFmj7BS1Keac0Os1TYtJ95pRfSSkT4R0JaSPhLSqN68f67dxQffv4i-SGuCnQK5WuMWk7-KWQn35P61_AAUqn18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859730416</pqid></control><display><type>article</type><title>High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Hara, Masayasu ; Nagasaki, Takaya ; Shiga, Kazuyoshi ; Takahashi, Hiroki ; Takeyama, Hiromitsu</creator><creatorcontrib>Hara, Masayasu ; Nagasaki, Takaya ; Shiga, Kazuyoshi ; Takahashi, Hiroki ; Takeyama, Hiromitsu</creatorcontrib><description>Purpose
We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy.
Methods
In this retrospective study, the pretreatment serum IL-6 and plasma vascular endothelial growth factor (VEGF) levels were measured in 113 patients with metastatic CRC. The cut-off values for these measurements, as determined by a receiver operating characteristic curve analysis, were 4.3 and 66 pg/mL, respectively. The median follow-up period was 19 months (range 1–40 months). Sixty-three patients had primary cancer, and 38 had a metachronous recurrence. Thirty patients underwent curative resection, and 71 underwent chemotherapy, 53 of whom received bevacizumab-containing chemotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier and multivariate Cox proportional hazards regression analyses.
Results
The plasma VEGF levels and positive
KRAS
mutation status were not associated with the outcomes. However, high serum IL-6 levels were significantly associated with poorer OS and PFS in comparison to low serum IL-6 levels. A Cox proportional hazards regression analysis showed that high serum IL-6 levels were an independent risk factor for a poor outcome.
Conclusion
In patients with metastatic CRC, high pretreatment serum IL-6 levels were associated with a poor outcome and bevacizumab resistance.</description><identifier>ISSN: 0941-1291</identifier><identifier>EISSN: 1436-2813</identifier><identifier>DOI: 10.1007/s00595-016-1404-7</identifier><identifier>PMID: 27549777</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab - administration & dosage ; Biomarkers, Tumor - blood ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - secondary ; Female ; Follow-Up Studies ; Humans ; Interleukin-6 - blood ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Original Article ; Retrospective Studies ; Risk Factors ; ROC Curve ; Surgery ; Surgical Oncology ; Survival Rate ; Time Factors ; Treatment Outcome ; Vascular Endothelial Growth Factor A - blood</subject><ispartof>Surgery today (Tokyo, Japan), 2017-04, Vol.47 (4), p.483-489</ispartof><rights>Springer Japan 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-c25ff165920d0fb950dea5e8d25ac942d1d67b9364d4146476f0f7d3d20af8b33</citedby><cites>FETCH-LOGICAL-c368t-c25ff165920d0fb950dea5e8d25ac942d1d67b9364d4146476f0f7d3d20af8b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00595-016-1404-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00595-016-1404-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27549777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hara, Masayasu</creatorcontrib><creatorcontrib>Nagasaki, Takaya</creatorcontrib><creatorcontrib>Shiga, Kazuyoshi</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Takeyama, Hiromitsu</creatorcontrib><title>High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab</title><title>Surgery today (Tokyo, Japan)</title><addtitle>Surg Today</addtitle><addtitle>Surg Today</addtitle><description>Purpose
We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy.
Methods
In this retrospective study, the pretreatment serum IL-6 and plasma vascular endothelial growth factor (VEGF) levels were measured in 113 patients with metastatic CRC. The cut-off values for these measurements, as determined by a receiver operating characteristic curve analysis, were 4.3 and 66 pg/mL, respectively. The median follow-up period was 19 months (range 1–40 months). Sixty-three patients had primary cancer, and 38 had a metachronous recurrence. Thirty patients underwent curative resection, and 71 underwent chemotherapy, 53 of whom received bevacizumab-containing chemotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier and multivariate Cox proportional hazards regression analyses.
Results
The plasma VEGF levels and positive
KRAS
mutation status were not associated with the outcomes. However, high serum IL-6 levels were significantly associated with poorer OS and PFS in comparison to low serum IL-6 levels. A Cox proportional hazards regression analysis showed that high serum IL-6 levels were an independent risk factor for a poor outcome.
Conclusion
In patients with metastatic CRC, high pretreatment serum IL-6 levels were associated with a poor outcome and bevacizumab resistance.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab - administration & dosage</subject><subject>Biomarkers, Tumor - blood</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - secondary</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Interleukin-6 - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><issn>0941-1291</issn><issn>1436-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhS0EotvCD-CC5sglYDuOnXBDFdBKlbjA2XLscTclsYPtLCr_iH-Jt1s4chq9eW-eNPoIecXoW0apepcp7YauoUw2TFDRqCdkx0QrG96z9inZ0UGwhvGBnZHznO8o5aKn9Dk546oTg1JqR35fTbd7yJi2BWY84JwhephCwTTj9n0KjawKVlMmDCXDz6nswbiDCRYdxAQLFpNLtS3YOMeEtpgZ7NFP76HsEdD7uoQYHlTcio0LggnuQSfMawwZoUSwe1xiXSaz3sM6bxlGPBg7_doWM74gz7yZM758nBfk26ePXy-vmpsvn68vP9w0tpV9aSzvvGeyGzh11I9DRx2aDnvHO2MHwR1zUo1DK4UTTEihpKdeudZxanw_tu0FeXPqXVP8sWEuepmyxXk2AeOWNeu7QbVUMFmj7BS1Keac0Os1TYtJ95pRfSSkT4R0JaSPhLSqN68f67dxQffv4i-SGuCnQK5WuMWk7-KWQn35P61_AAUqn18</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Hara, Masayasu</creator><creator>Nagasaki, Takaya</creator><creator>Shiga, Kazuyoshi</creator><creator>Takahashi, Hiroki</creator><creator>Takeyama, Hiromitsu</creator><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab</title><author>Hara, Masayasu ; Nagasaki, Takaya ; Shiga, Kazuyoshi ; Takahashi, Hiroki ; Takeyama, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-c25ff165920d0fb950dea5e8d25ac942d1d67b9364d4146476f0f7d3d20af8b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab - administration & dosage</topic><topic>Biomarkers, Tumor - blood</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - secondary</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Interleukin-6 - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hara, Masayasu</creatorcontrib><creatorcontrib>Nagasaki, Takaya</creatorcontrib><creatorcontrib>Shiga, Kazuyoshi</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Takeyama, Hiromitsu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery today (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hara, Masayasu</au><au>Nagasaki, Takaya</au><au>Shiga, Kazuyoshi</au><au>Takahashi, Hiroki</au><au>Takeyama, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab</atitle><jtitle>Surgery today (Tokyo, Japan)</jtitle><stitle>Surg Today</stitle><addtitle>Surg Today</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>47</volume><issue>4</issue><spage>483</spage><epage>489</epage><pages>483-489</pages><issn>0941-1291</issn><eissn>1436-2813</eissn><abstract>Purpose
We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy.
Methods
In this retrospective study, the pretreatment serum IL-6 and plasma vascular endothelial growth factor (VEGF) levels were measured in 113 patients with metastatic CRC. The cut-off values for these measurements, as determined by a receiver operating characteristic curve analysis, were 4.3 and 66 pg/mL, respectively. The median follow-up period was 19 months (range 1–40 months). Sixty-three patients had primary cancer, and 38 had a metachronous recurrence. Thirty patients underwent curative resection, and 71 underwent chemotherapy, 53 of whom received bevacizumab-containing chemotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier and multivariate Cox proportional hazards regression analyses.
Results
The plasma VEGF levels and positive
KRAS
mutation status were not associated with the outcomes. However, high serum IL-6 levels were significantly associated with poorer OS and PFS in comparison to low serum IL-6 levels. A Cox proportional hazards regression analysis showed that high serum IL-6 levels were an independent risk factor for a poor outcome.
Conclusion
In patients with metastatic CRC, high pretreatment serum IL-6 levels were associated with a poor outcome and bevacizumab resistance.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>27549777</pmid><doi>10.1007/s00595-016-1404-7</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-1291 |
| ispartof | Surgery today (Tokyo, Japan), 2017-04, Vol.47 (4), p.483-489 |
| issn | 0941-1291 1436-2813 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859730416 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Biomarkers, Tumor - blood Colorectal Neoplasms - diagnosis Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - secondary Female Follow-Up Studies Humans Interleukin-6 - blood Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Original Article Retrospective Studies Risk Factors ROC Curve Surgery Surgical Oncology Survival Rate Time Factors Treatment Outcome Vascular Endothelial Growth Factor A - blood |
| title | High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T16%3A26%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20serum%20levels%20of%20interleukin-6%20in%20patients%20with%20advanced%20or%20metastatic%20colorectal%20cancer:%20the%20effect%20on%20the%20outcome%20and%20the%20response%20to%20chemotherapy%20plus%20bevacizumab&rft.jtitle=Surgery%20today%20(Tokyo,%20Japan)&rft.au=Hara,%20Masayasu&rft.date=2017-04-01&rft.volume=47&rft.issue=4&rft.spage=483&rft.epage=489&rft.pages=483-489&rft.issn=0941-1291&rft.eissn=1436-2813&rft_id=info:doi/10.1007/s00595-016-1404-7&rft_dat=%3Cproquest_cross%3E1859730416%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859730416&rft_id=info:pmid/27549777&rfr_iscdi=true |